# Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea

> **NCT04541134** · PHASE3 · UNKNOWN · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Primary Dysmenorrhea

## Interventions

- **DRUG:** Pelubiprofen 45mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04541134
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-30
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-08-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04541134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04541134, "Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT04541134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*